IP Library › Patent Application 15520401

Patent Application

App. No. 15/520,401

NOVEL ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS AND METHODS OF USE

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US None
App. No.: 15/520,401

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present disclosure provides novel linker-cytotoxin conjugates and antibody-drug conjugates, including homogenous antibody-drug conjugates, comprising the novel linker-cytotoxin conjugates.

Claims (83)

1 . An antibody-drug conjugate of the following formula (I):

or a pharmaceutically acceptable salt thereof,

wherein:

A is an antibody;

the two depicted cysteine residues are from an opened cysteine-cysteine disulfide bond in A;

L is a cleavable or a noncleavable linker;

CTX is an auristatin, a pyrrolobenzodiazepine, calicheamicin, doxorubicin, camptothecin, duocarmycin, DM1, DM4, a maytansinoid, or a tubulysin, wherein CTX is bonded to L by an amide bond, a carbamate bond, a disulfide bond, an ether bond, a thioether bond, or an ester bond;

the bond represents a single or a double bond; and

n is an integer of 1 to 4.

2 . The antibody-drug conjugate of claim 1 , which has the following formula (Ia) or formula (Ib):

3 . (canceled)

4 . The antibody-drug conjugate of claim 1 , wherein CTX is an auristatin bonded to L by an amide bond or a carbamate bond.

5 . The antibody-drug conjugate of claim 4 , wherein CTX is monomethylauristatin F.

6 . The antibody-drug conjugate of claim 4 , wherein CTX is monomethylauristatin E.

7 .- 8 . (canceled)

9 . The antibody-drug conjugate of claim 8 , wherein L is —(CH 2 ) m C(O)—, wherein m is an integer of 5 to 11.

10 .- 11 . (canceled)

12 . The antibody-drug conjugate of claim 1 , wherein A is a monoclonal antibody, and optionally wherein A comprises two heavy chains and two light chains wherein one or more cysteines in the hinge region of the heavy chains of A have been replaced by another amino acid.

13 . (canceled)

14 . The antibody-drug conjugate of claim 1 , wherein A is an antibody that is specific to a cancer antigen, and optionally wherein the cancer antigen is CD33 (Siglec3), CD30 (TNFRSF8), HER2 (ERbB-2), EGFR, VEGF-A, CD22 (Siglec2), CD79b, CD22 (Siglec2), GPNMB, CD19 (B4), CD56 (NCAM), CD138 (SDC1), PSMA (FOLH1), CD74 (DHLAG), PSMA (FOLH1), CEACAM5 (CD66e), EGP1 (TROP2), FOLR1, CD37, Muc-16, Endothelial receptor (ETB), STEAP1, CD19, CD20, CD70 (TNFSF7), SLC44A4, Nectin-4, AGS-16, Guanylyl cyclase C, Muc-1, CD70 (TNFSF7), Her3 (ErbB-3), mesothelin, NaPi2b, LIV1, SLITRK6, ENPP3, TF, 5T4, BCMA, SCLC, Integrin, CD70 (TNFSF7), CA9 (MN), CFC1B (Cripto), CD98, C10orf54, or C16orf54.

15 .- 17 . (canceled)

18 . The antibody-drug conjugate of claim 1 , wherein the opened cysteine-cysteine disulfide bond in A is an interchain disulfide bond.

19 . (canceled)

20 . The antibody-drug conjugate of claim 1 or 18 , wherein L is —(CH 2 ) 5 C(O)— and n is 4.

21 . (canceled)

22 . The antibody-drug conjugate of claim 1 , which is of one the following formulas:

or a pharmaceutically acceptable salt thereof.

23 .- 29 . (canceled)

30 . The antibody-drug conjugate of claim 1 , wherein A is trastuzumab, bevacizumab, rituximab, cetuximab, IGN523, or IGN786.

31 . The antibody-drug conjugate of claim 1 , wherein A comprises:

a VH sequence that comprises SEQ ID NO: 1 and a VL sequence that comprises SEQ ID NO: 2; a VH sequence that comprises SEQ ID NO: 3 and a VL sequence that comprises SEQ ID NO: 4;

a VH sequence that comprises SEQ ID NO: 5 and a VL sequence that comprises SEQ ID NO: 6;

a heavy chain sequence that comprises SEQ ID NO: 7 and a light chain sequence that comprises SEQ ID NO: 11;

a heavy chain sequence that comprises SEQ ID NO: 8 and a light chain sequence that comprises SEQ ID NO: 11;

a heavy chain sequence that comprises SEQ ID NO: 9 and a light chain sequence that comprises SEQ ID NO: 11;

a heavy chain sequence that comprises SEQ ID NO: 10 and a light chain sequence that comprises SEQ ID NO: 11;

a heavy chain sequence that comprises SEQ ID NO: 12 and a light chain sequence that comprises SEQ ID NO: 16;

a heavy chain sequence that comprises SEQ ID NO: 13 and a light chain sequence that comprises SEQ ID NO: 16;

a heavy chain sequence that comprises SEQ ID NO: 14 and a light chain sequence that comprises SEQ ID NO: 16; or

a heavy chain sequence that comprises SEQ ID NO: 15 and a light chain sequence that comprises SEQ ID NO: 16;

a heavy chain sequence that comprises SEQ ID NO: 17 and a light chain sequence that comprises SEQ ID NO: 21;

a heavy chain sequence that comprises SEQ ID NO: 18 and a light chain sequence that comprises SEQ ID NO: 21;

a heavy chain sequence that comprises SEQ ID NO: 19 and a light chain sequence that comprises SEQ ID NO: 21;

a heavy chain sequence that comprises SEQ ID NO: 20 and a light chain sequence that comprises SEQ ID NO: 21;

a heavy chain sequence that comprises SEQ ID NO: 22 and a light chain sequence that comprises SEQ ID NO: 26;

a heavy chain sequence that comprises SEQ ID NO: 23 and a light chain sequence that comprises SEQ ID NO: 26;

a heavy chain sequence that comprises SEQ ID NO: 24 and a light chain sequence that comprises SEQ ID NO: 26; or

a heavy chain sequence that comprises SEQ ID NO: 25 and a light chain sequence that comprises SEQ ID NO: 26.

32 .- 35 . (canceled)

36 . A linker-cytotoxin conjugate of one of the following formulas (IIa), (IIb), and (IIc):

or an enantiomer, diasteriomer, or mixtures thereof;

wherein:

L is a cleavable or noncleavable linker; and

37 . The linker-cytotoxin conjugate of claim 36 , wherein CTX is an auristatin bonded to L by an amide bond or a carbamate bond.

38 .- 41 . (canceled)

42 . The linker-cytotoxin conjugate of claim 36 , wherein L is —(CH 2 ) m C(O)—, wherein m is an integer of 5 to 11.

43 .- 44 . (canceled)

45 . The linker-cytotoxin conjugate of claim 36 , which has one of the following structures:

46 .- 53 . (canceled)

54 . A pharmaceutical composition comprising the antibody-drug conjugate of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable diluent, carrier or excipient.

55 . A method of treating a cancer by administering to a human suffering therefrom an effective amount of the antibody-drug conjugate of claim 1 or a pharmaceutically acceptable thereof.

56 .- 106 . (canceled)

107 . An antibody-drug conjugate comprising an antibody comprising: